Healthcare Associated Infections (HAI)

George Thompson, MD, principal investigator of the STRIVE study discusses optimal dosing for rezafungin in treating candidemia and/or invasive candidiasis.

Dale N Gerding, MD, provides insight about prevention options for C diff that are expected in the future.

Contamination is a common aspect of nasal saline irrigations.

Nimish Patel, PharmD, PhD, describes his study, which compared fidaxomicin with oral vancomycin in early targeted therapy of C diff.

Scientists sought to figure out whether rapid diagnostic tests could be used to determine the susceptibility of P aeruginosa to 2 new therapies. The answer was yes, but with caveats.

Yoav Golan, MD, discusses the paradigm shift occurring in treatment for ABSSSI and how to motivate clinicians to buy into new programs and protocols.

Duodenoscopes are at fault for another infectious disease outbreak, and this time it's with a highly-resistant bacteria.

The program calls for new research and development incentives, veterinary stewardship, and enhanced surveillance.

Barbara Wells Trautner, MD, PhD, explains how overtreating asymptomatic bacteriuria can lead to antibiotic resistance or incorrect diagnoses.

Ceftolozane and tazobactam proves noninferior to meropenem in a pivotal phase 3 trial of adult patients with HABP or VABP.

Common skin bacteria have gained resistance to multiple antibiotics.

A new study is the first to identify eosinophil counts as a predictor of outcomes in human patients.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, explains how rapid diagnostics interplay with prediction scores in antimicrobial stewardship programs.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.

Additional evidence supports the use of oritavancin as a cost-saving outpatient treatment for acute bacterial skin and skin structure infections (ABSSTIs) in patients who would otherwise be admitted to the hospital for therapy.

Can we find an alternative for chlorhexidine gluconate?

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The results are significant given the ongoing debate regarding the role of contact precautions for the gram-positive bacteria.

Yoav Golan, MD, discusses trends in the incidence of acute bacterial skin and skin structure infections, standard protocols for treatment, and the challenges clinicians continue to face.

Aerosolized antibiotics are a reasonable adjunctive option to treat multidrug-resistant gram-negative pneumonia due to excellent pulmonary concentrations and few adverse effects.

Candidemia is a significant risk factor for C difficile infection in hospital patients.

Moving away from the standard course of IV antibiotics.

The PDUFA action date has been set for February 13, 2019.

As health care services move into the outpatient setting, is infection control being overlooked?

Barbara Wells Trautner, MD, PhD, discusses finding alternatives to fluoroquinolones and facilitating patient communication to improve outcomes.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Gram-positive multidrug-resistant infections may be managed effectively with a single dose of long-acting lipo­glycopeptide antibiotics in the outpatient setting; however, careful patient selection is important for maximizing the cost-benefit of these relatively expensive drugs.

Investigators who evaluated the death of a 78-year-old man following a blood transfusion say there’s little that could have been done to prevent the infection.

Fecal microbiota transplantation (FMT) is a widely accepted, safe, and effective treatment for recurrent Clostridium diffi­cile infection (rCDI), but does the cure endure?